人类微生物组市场－全球产业规模、份额、趋势、机会和预测，按产品、应用、疾病、技术、类型、地区和竞争细分，2020-2030 年

2024年，全球人体微生物组市值为6.1525亿美元，预计2030年将达到15.2405亿美元，复合年增长率为16.28%。全球人体微生物组市场正在经历重大转型，这得益于科学界对微生物组对人类健康和疾病影响的日益认可，以及製药和生物技术公司不断增加的投资。该市场涵盖诊断、治疗和医疗保健解决方案的开发，旨在利用或改变人体微生物组（由栖息在人体内的数万亿微生物组成），以改善医疗效果。

关键市场驱动因素

癌症治疗的应用日益增多

主要市场挑战

科学的复杂性和对微生物组功能的有限理解

主要市场趋势

转向个人化微生物组疗法

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：人类微生物组市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 副产品（益生元、益生菌、医疗食品、补充剂、其他）
  • 按应用（治疗、诊断）
  • 依疾病（传染病、内分泌及代谢疾病、肠胃疾病、癌症、其他）
  • 按技术（基因体学、蛋白质体学、代谢体学）
  • 按类型（FMT、胜肽、活生物治疗产品、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美人类微生物组市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲人类微生物组市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太地区人体微生物组市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美人类微生物组市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲人类微生物组市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球人类微生物组市场：SWOT 分析

第 14 章：竞争格局

• Enterome Bioscience SA
• Yakult Honsha Co. Ltd.
• 4 D Pharma
• Evelo Biosciences
• Seres Therapeutics Inc.
• Vedanta Biosciences
• Second Genome Inc.
• Quantibiome
• Rebiotix Inc.
• Microbiome Therapeutics LLC

第 15 章：策略建议

第16章调查会社について・免责事项

Global Human Microbiome market was valued at USD 615.25 Million in 2024 and is expected to reach USD 1524.05 Million by 2030 with a CAGR of 16.28%. The Global Human Microbiome Market is experiencing a significant transformation, fueled by growing scientific recognition of the microbiome's impact on human health and disease, along with increasing investments from pharmaceutical and biotechnology firms. This market encompasses the development of diagnostics, therapeutics, and healthcare solutions aimed at leveraging or modifying the human microbiota comprising trillions of microorganisms that inhabit the human body for improved medical outcomes.

Key Market Drivers

Increased Application in Cancer Treatment

Research has demonstrated that the human microbiome plays a crucial role in modulating immune responses, which directly impacts the efficacy of immunotherapies and chemotherapy. Certain gut microbiota strains have been found to enhance the effectiveness of immune checkpoint inhibitors, leading to improved patient outcomes. Biotech firms and pharmaceutical companies are investing in microbiome-derived drugs that can be used as adjunct therapies to traditional cancer treatments. These therapies aim to reduce treatment-related toxicity, improve drug absorption, and enhance immune system resilience.

The surge in clinical trials exploring microbiome-based interventions for cancer treatment is accelerating market growth. Studies are investigating how gut microbiota composition influences cancer progression and response to therapy. Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) has established itself as a premier clinical trial site, earning recognition from leading global cancer research institutions and pharmaceutical companies. With a track record of participation in over 300 national and international clinical trials, the center plays a pivotal role in advancing oncology research and innovative cancer therapies across diverse cancer types. Leading biotech firms and research institutions are forming strategic partnerships to develop microbiome-based cancer solutions. Increased funding from government agencies and private investors is driving innovation in microbiome therapeutics.

The integration of microbiome profiling into precision oncology is enabling personalized treatment plans tailored to individual patients. AI-driven microbiome analysis is helping identify biomarkers that predict cancer treatment responses. Regulatory bodies are recognizing the potential of microbiome-based therapies, leading to faster approvals and standardization efforts. The market is witnessing expansion into emerging economies, where cancer prevalence is rising.

Key Market Challenges

Scientific Complexity and Limited Understanding of Microbiome Functions

One of the most fundamental challenges impeding market growth is the incomplete and complex understanding of the human microbiome's structure, function, and interactions with host physiology. Despite major research advancements, scientists still face difficulties in: Differentiating between beneficial, neutral, and harmful microbes, Understanding causal relationships between microbiome imbalances and specific diseases, Establishing universal biomarkers or reference ranges for "healthy" microbiota.

This scientific uncertainty limits the ability of researchers and companies to design effective, targeted, and reproducible microbiome-based therapies. Moreover, it complicates clinical trial design and makes it harder to validate efficacy, slowing product development and investor confidence.

Key Market Trends

Shift Toward Personalized Microbiome-Based Therapies

The most significant trends fueling market growth is the rapid evolution of personalized medicine powered by microbiome insights. As scientific understanding of the human microbiome deepens, it is becoming increasingly clear that microbial compositions vary significantly across individuals. This has led to a paradigm shift from generalized probiotic or therapeutic approaches toward personalized microbiome interventions, including: Tailored probiotics and synbiotics based on individual gut flora, Microbiome profiling and diagnostics to guide treatment decisions, Customized dietary recommendations to optimize gut health and disease prevention.

This trend aligns with the broader healthcare movement toward precision medicine, offering more effective, safer, and targeted interventions. As genomic sequencing and microbiome mapping technologies become more accessible and affordable, personalized microbiome-based therapies are poised to redefine patient care.

Key Market Players

• Enterome Bioscience SA
• Yakult Honsha Co. Ltd.
• 4 D Pharma
• Evelo Biosciences
• Seres Therapeutics Inc.
• Vedanta Biosciences
• Second Genome Inc.
• Quantibiome
• Rebiotix Inc.
• Microbiome Therapeutics LLC

Report Scope:

In this report, the Global Human Microbiome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Microbiome Market, By Product:

• Prebiotics
• Probiotics
• Medical Food
• Supplements
• Others

Human Microbiome Market, By Application:

• Therapeutic
• Diagnostic

Human Microbiome Market, By Disease:

• Infectious Disease
• Endocrine and Metabolic Disorders
• Gastrointestinal Diseases
• Cancer
• Others

Human Microbiome Market, By Technology:

• Genomics
• Proteomics
• Metabolomics

Human Microbiome Market, By Type:

• FMT
• Peptide
• Live Biotherapeutic Product
• Others

Human Microbiome Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Microbiome Market.

Available Customizations:

Global Human Microbiome market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Human Microbiome Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Prebiotics, Probiotics, Medical Food, Supplements, Others)
  • 5.2.2. By Application (Therapeutic, Diagnostic)
  • 5.2.3. By Disease (Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, Others)
  • 5.2.4. By Technology (Genomics, Proteomics, Metabolomics)
  • 5.2.5. By Type (FMT, Peptide, Live Biotherapeutic Product, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Human Microbiome Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Disease
  • 6.2.4. By Technology
  • 6.2.5. By Type
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Microbiome Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Disease
      • 6.3.1.2.4. By Technology
      • 6.3.1.2.5. By Type
  • 6.3.2. Canada Human Microbiome Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Disease
      • 6.3.2.2.4. By Technology
      • 6.3.2.2.5. By Type
  • 6.3.3. Mexico Human Microbiome Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Disease
      • 6.3.3.2.4. By Technology
      • 6.3.3.2.5. By Type

7. Europe Human Microbiome Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Disease
  • 7.2.4. By Technology
  • 7.2.5. By Type
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Microbiome Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Disease
      • 7.3.1.2.4. By Technology
      • 7.3.1.2.5. By Type
  • 7.3.2. United Kingdom Human Microbiome Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Disease
      • 7.3.2.2.4. By Technology
      • 7.3.2.2.5. By Type
  • 7.3.3. Italy Human Microbiome Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Disease
      • 7.3.3.2.4. By Technology
      • 7.3.3.2.5. By Type
  • 7.3.4. France Human Microbiome Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Disease
      • 7.3.4.2.4. By Technology
      • 7.3.4.2.5. By Type
  • 7.3.5. Spain Human Microbiome Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Disease
      • 7.3.5.2.4. By Technology
      • 7.3.5.2.5. By Type

8. Asia-Pacific Human Microbiome Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Disease
  • 8.2.4. By Technology
  • 8.2.5. By Type
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human Microbiome Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Disease
      • 8.3.1.2.4. By Technology
      • 8.3.1.2.5. By Type
  • 8.3.2. India Human Microbiome Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Disease
      • 8.3.2.2.4. By Technology
      • 8.3.2.2.5. By Type
  • 8.3.3. Japan Human Microbiome Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Disease
      • 8.3.3.2.4. By Technology
      • 8.3.3.2.5. By Type
  • 8.3.4. South Korea Human Microbiome Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Disease
      • 8.3.4.2.4. By Technology
      • 8.3.4.2.5. By Type
  • 8.3.5. Australia Human Microbiome Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Disease
      • 8.3.5.2.4. By Technology
      • 8.3.5.2.5. By Type

9. South America Human Microbiome Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Disease
  • 9.2.4. By Technology
  • 9.2.5. By Type
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human Microbiome Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Disease
      • 9.3.1.2.4. By Technology
      • 9.3.1.2.5. By Type
  • 9.3.2. Argentina Human Microbiome Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Disease
      • 9.3.2.2.4. By Technology
      • 9.3.2.2.5. By Type
  • 9.3.3. Colombia Human Microbiome Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Disease
      • 9.3.3.2.4. By Technology
      • 9.3.3.2.5. By Type

10. Middle East and Africa Human Microbiome Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Disease
  • 10.2.4. By Technology
  • 10.2.5. By Type
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Human Microbiome Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Disease
      • 10.3.1.2.4. By Technology
      • 10.3.1.2.5. By Type
  • 10.3.2. Saudi Arabia Human Microbiome Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Disease
      • 10.3.2.2.4. By Technology
      • 10.3.2.2.5. By Type
  • 10.3.3. UAE Human Microbiome Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Disease
      • 10.3.3.2.4. By Technology
      • 10.3.3.2.5. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Human Microbiome Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Enterome Bioscience SA
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Yakult Honsha Co. Ltd.
• 14.3. 4 D Pharma
• 14.4. Evelo Biosciences
• 14.5. Seres Therapeutics Inc.
• 14.6. Vedanta Biosciences
• 14.7. Second Genome Inc.
• 14.8. Quantibiome
• 14.9. Rebiotix Inc.
• 14.10.Microbiome Therapeutics LLC

15. Strategic Recommendations

16. About Us & Disclaimer